Forward Looking Statement

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.
Our Vision

**A trusted advisor**
transforming patients’ lives worldwide
with pioneering molecular diagnostics

**The global leader**
in personalized medicine
Myriad Leads Personalized Medicine Industry

Unique Scale and Expertise Creates Sustainable Competitive Advantage

- **OVER 27** years since company was founded in 1991
- **1** first profitable R&D driven personalized medicine company
- **~6M** tests performed; unmatched reputation for quality
- **~3K** employees dedicated to the Myriad mission
- **OVER 1K** scientific publications to date; extensive research capabilities

- **3** expertise with all three types of biomarkers (DNA, RNA and proteins)
- **1** only personalized medicine company with broad regulatory experience
- **OVER 100K** ordering physicians since inception; deep relationships
- **143** countries have ordered our products
- **>95%** of U.S. payers are in-network

years since company was founded in 1991, first profitable R&D driven personalized medicine company, tests performed; unmatched reputation for quality, employees dedicated to the Myriad mission, scientific publications to date; extensive research capabilities, expertise with all three types of biomarkers (DNA, RNA and proteins), only personalized medicine company with broad regulatory experience, ordering physicians since inception; deep relationships, countries have ordered our products, of U.S. payers are in-network
Myriad’s 4 in 6 Strategy

Answering patients’ 4 most pressing questions

- Will I get a disease?
- Do I have a disease?
- Should I treat this disease?
- How should I treat this disease?

In 6 medical specialties

- Women’s Health
- Neuroscience
- Oncology
- Autoimmune
- Urology
- Dermatology
# Most Attractive Product Pipeline in Diagnostic Industry

11 Products Addressing $30B of Global Market Potential

<table>
<thead>
<tr>
<th>PRODUCT</th>
<th>KEY QUESTION ANSWERED</th>
<th>DISTRIBUTION</th>
<th>GLOBAL TAM</th>
<th>KEY RECENT DEVELOPMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>myRisk</strong></td>
<td>Will I get cancer?</td>
<td></td>
<td>$5.0B</td>
<td>ASBS guidelines recommend testing for all breast cancer patients</td>
</tr>
<tr>
<td><strong>genesight</strong></td>
<td>What drugs will work best for my depression?</td>
<td></td>
<td>$10.0B</td>
<td>GeneSight GUIDED study published</td>
</tr>
<tr>
<td><strong>Foresight</strong></td>
<td>Is my child at risk for a genetic condition?</td>
<td></td>
<td>$4.0B</td>
<td>3x expansion in sales team in Jan. 2019</td>
</tr>
<tr>
<td><strong>Vectra</strong></td>
<td>Is my RA under control?</td>
<td></td>
<td>$3.0B</td>
<td>Demonstrated 3-5x better than any other disease activity measure</td>
</tr>
<tr>
<td><strong>Prolearis</strong></td>
<td>Do I have an aggressive form of prostate cancer?</td>
<td></td>
<td>$1.5B</td>
<td>New NCCN guidelines led to new coverage from commercial payers covering over 27M lives</td>
</tr>
<tr>
<td><strong>EndoPredict</strong></td>
<td>How aggressive is my breast cancer and how should I treat it?</td>
<td></td>
<td>$0.7B</td>
<td>&gt;90% of commercial payers now cover the test</td>
</tr>
<tr>
<td><strong>BRACAnalysis CDx</strong></td>
<td>Am I a good candidate for a PARP inhibitor?</td>
<td></td>
<td>$5.0B</td>
<td>Positive pancreatic cancer data from AstraZeneca POLO study</td>
</tr>
<tr>
<td><strong>myPath</strong></td>
<td>Is this skin lesion melanoma?</td>
<td></td>
<td>$0.8B</td>
<td>Eight commercial payer decisions and final Medicare LCD</td>
</tr>
</tbody>
</table>

**Key Clinical Areas:**

- Oncology
- Women’s Health
- Neuroscience
- Autoimmune
- Urology
- Dermatology
Critical Success Factors to Achieve Strategic Goals

- Build upon solid hereditary cancer foundation
- Improve profitability with Elevate 2020
- Increase RNA kit revenue internationally
- Expand reimbursement coverage for new products
- Grow new product volume

STRATEGIC GOALS

- >10% REVENUE GROWTH
- >30% OPERATING MARGIN
- 7 PRODUCTS >$50M
- >10% INT’L REVENUE
- Grow new product volume
Growing Volume

• Market less than 15% penetrated
• 7% CAGR since FY13
• 9 sequential quarters with YoY growth
• New indications added 175,000 eligible patients per year in the U.S. and Japan
• riskScore driving deeper penetration – Developed new version for Hispanic women
• BRACAnalysis CDx approved in first-line maintenance for ovarian cancer
• New pancreatic cancer data for BRACAnalysis CDx
• New CDx collaboration in prostate cancer

Stable Pricing Outlook

• 6 consecutive quarters with stable pricing
• Long term contracts provide stable pricing into FY20
• UNH contract fixed until FY21
• Smaller price premium easily justifiable

Hereditary Cancer Revenue*
Diversification with Rapidly Expanding New Product Volume

>5x Volume Growth Over Last Five Years

New Product Diversification (including Prenatal)

- 76% of volume in FY18 vs. 1% in FY13
- 42% CAGR FY13-FY18
- Consistent double-digit organic new product volume growth
- Counsyl acquisition (closed in FY19) further diversifies the company into high-growth prenatal market
New Products Have Outstanding Growth Prospects
Markets Remain Highly Underpenetrated

VOLUME RELATIVE TO GLOBAL MARKET OPPORTUNITY

- Hereditary Cancer: 15%
- Foresight: 6%
- Prequel™ Prenatal Screen: 2%
- MyPath™: 1%
- Vectra™: 2%
- Prolaris®: 5%
- EndoPredict®: 1%
- <1%
Increasing Payer Coverage Fuels Growth Potential

Current Reimbursed Addressable Market (RAM) >$1.6B

### CURRENT U.S. COVERAGE

<table>
<thead>
<tr>
<th>Product</th>
<th>RAM 1</th>
<th>TAM 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>EndoPredict</td>
<td>$240M</td>
<td>$260M</td>
</tr>
<tr>
<td>Prolaris</td>
<td>$330M</td>
<td>$600M</td>
</tr>
<tr>
<td>Prequel</td>
<td>$2,800M</td>
<td>$5,200M</td>
</tr>
<tr>
<td>Vectra</td>
<td>$720M</td>
<td>$3,000M</td>
</tr>
<tr>
<td>GeneSight</td>
<td>$300M</td>
<td>$5,000M</td>
</tr>
<tr>
<td>myPath Melanoma</td>
<td>$4M</td>
<td>$450M</td>
</tr>
</tbody>
</table>

Recent Payer Progress

- EndoPredict NCCN guidelines and payer coverage decisions increase to 90%
- NCCN guidelines for Prolaris increase Medicare and commercial coverage to 56%
- myPath Melanoma receives final LCD from Medicare which would increase coverage to 36%
- Prenatal average risk receives positive tech assessment from BCBS
- Back in-network with UNH for prenatal testing
- Publication of GeneSight GUIDED study
- CareFirst covers GeneSight
- Kroger becomes first large employer to cover GeneSight
Steady International Growth Led by Kit Products

45% Five-year CAGR

Near-Term Growth Drivers

- Approval for BRACAnalysis CDx in metastatic BC and ovarian cancer in Japan
- Filed for Japanese regulatory approval for hereditary cancer testing
- Positive NICE decision for EndoPredict reimbursement in UK
- EndoPredict reimbursement in Greece and first region of Italy
Meaningful Profitability Improvement Through Elevate 2020
Exceeded $50M Program Goal in Only Five Quarters

Elevate 2020 Progress
• All business units except Dermatology now profitable
• Organic adjusted operating margins have increased 550 bp FY17 to FY19 YTD
• Vectra and International laboratory moves completed at the end of the fiscal 2Q19
• Additional projects underway

Elevate 2020 savings lead to 35% adjusted EPS growth in 3Q19

* Excludes Counsyl
Financial Overview
Substantial Opportunity for Earnings Growth

GeneSight and Prenatal Opportunities Support Tripling of Adjusted EPS

Oppportunity to triple adjusted EPS

Multiple material growth drivers

GeneSight

Prenatal

Other

Adjusted EPS run rate FY19 YTD
(excludes Counsyl – Accretive by 4Q19 due to cost synergies)

$1.97
**GeneSight Opportunity for Transformational Growth**

Reimbursement drives ASP Increase and Primary Care Launch more than Doubles Volume

---

### ASP Expansion Opportunity

- **FY18 ASP ≈$400 per test**
- GUIDED study accepted for publication
- Optum Health study demonstrated >$6,000 per test in cost savings
- 25% of commercial lives contracted at $2,000
- 60% of commercial lives have received complete dossier

### Volume Growth Opportunity

- >300,000 run rate growing at >20% YoY
- Primary care launch more than doubles market
- U.S. market potential ≈3M tests per year

---

**INCREMENTAL REVENUE AND ADJUSTED EPS***

<table>
<thead>
<tr>
<th>GENESIGHT TEST VOLUME</th>
<th>GENESIGHT TEST ASP</th>
</tr>
</thead>
<tbody>
<tr>
<td>300K</td>
<td>$400</td>
</tr>
<tr>
<td>500K</td>
<td>$600</td>
</tr>
<tr>
<td>700K</td>
<td>$1,000</td>
</tr>
<tr>
<td>900K</td>
<td>$2,000</td>
</tr>
</tbody>
</table>

**Incremental Revenue in millions**

<table>
<thead>
<tr>
<th>GENESIGHT TEST VOLUME</th>
<th>GENESIGHT TEST ASP</th>
</tr>
</thead>
<tbody>
<tr>
<td>300K</td>
<td></td>
</tr>
<tr>
<td>500K</td>
<td></td>
</tr>
<tr>
<td>700K</td>
<td></td>
</tr>
<tr>
<td>900K</td>
<td></td>
</tr>
</tbody>
</table>

* Assumes 65% revenue drop down
Market Growth and Share Accelerates through Broader Reach and Guidelines

Volume Growth Opportunity
- Tripling sales reps Jan 2019
- ACOG endorsement of average risk coverage anticipated in CY19
- ECS replacing basic screening as standard of care
- One-stop-shop portfolio available through industry-leading app called Myriad Complete

ASP Expansion Opportunity
- Average risk coverage for NIPS
- Microdeletions for NIPS
- ECS coverage with commercial insurers and Medicaid

INCREMENTAL REVENUE AND ADJUSTED EPS*

<table>
<thead>
<tr>
<th>Myriad Market Share</th>
<th>Incremental Revenue in millions</th>
<th>Adjusted EPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>13%</td>
<td>$0</td>
<td>$0.17</td>
</tr>
<tr>
<td>15%</td>
<td>$32</td>
<td>$0.59</td>
</tr>
<tr>
<td>20%</td>
<td>$113</td>
<td>$1.01</td>
</tr>
<tr>
<td>25%</td>
<td>$194</td>
<td>$1.17</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Prenatal Market 5-Year CAGR</th>
<th>Incremental Revenue in millions</th>
<th>Adjusted EPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>8%</td>
<td>$20</td>
<td>$0.10</td>
</tr>
<tr>
<td></td>
<td>$56</td>
<td>$0.29</td>
</tr>
<tr>
<td></td>
<td>$144</td>
<td>$0.75</td>
</tr>
<tr>
<td></td>
<td>$233</td>
<td>$1.21</td>
</tr>
<tr>
<td>10%</td>
<td>$42</td>
<td>$0.22</td>
</tr>
<tr>
<td></td>
<td>$81</td>
<td>$0.42</td>
</tr>
<tr>
<td></td>
<td>$178</td>
<td>$0.92</td>
</tr>
<tr>
<td></td>
<td>$275</td>
<td>$1.43</td>
</tr>
<tr>
<td>12%</td>
<td>$78</td>
<td>$0.40</td>
</tr>
<tr>
<td></td>
<td>$122</td>
<td>$0.63</td>
</tr>
<tr>
<td></td>
<td>$232</td>
<td>$1.21</td>
</tr>
<tr>
<td></td>
<td>$343</td>
<td>$1.78</td>
</tr>
</tbody>
</table>

Incremental Revenue in millions * Assumes 40% revenue drop down
Substantial Opportunity for Earnings Growth
GeneSight and Prenatal Opportunities Support Tripling of Adjusted EPS

Opportunity to triple adjusted EPS

Multiple material growth drivers

Adjusted EPS run rate FY19 YTD
(excludes Counsyl – Accretive by 4Q19 due to cost synergies)

GeneSight

Prenatal

Other

$1.97
Uses of Cash
Continued Opportunity to Deploy Capital to Maximize Shareholder Returns

<table>
<thead>
<tr>
<th>USES OF CASH</th>
<th>CURRENT FOCUS</th>
<th>GOAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D</td>
<td>10% of revenue</td>
<td>Invest in new product reimbursement and differentiation studies</td>
</tr>
<tr>
<td>M&amp;A</td>
<td>Integration of Counsyl</td>
<td>Assess opportunities that fit strategy with potential for near-term accretion</td>
</tr>
<tr>
<td>Debt Repayment</td>
<td>$263M at end of 3Q19</td>
<td>Reduce with excess free cash flow</td>
</tr>
<tr>
<td>Share Repurchase</td>
<td>$124M authorized*</td>
<td>$50M ASR completed in 2Q19; continue opportunistic purchases</td>
</tr>
</tbody>
</table>

*After completion of current $50M ASR
Myriad: The Investment Thesis

Personalized medicine is entering a hyper-growth phase

Molecular diagnostics are the keystone to improving patient outcomes and eliminating wasted spend

Myriad is the global leader in this market

Multiple catalysts can triple earnings

Compelling investment opportunity